Bio-rad Laboratories, Inc. · NYSE:BIO
Bio-rad Laboratories — Jefferies Healthcare Conference 2023
18 slides from Bio-rad Laboratories's conference presentation, Jun 8, 2023
Slide 1: Jefferies Healthcare Conference
Jefferies Healthcare Conference June 8, 2023 Bio-Rad Laboratories, Inc. 1
Slide 2: Forward-Looking Statements & Use of Non-GAAP Reporting
Forward-Looking Statements & Use of Non-GAAP Reporting Forward-looking Statements. Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management’s goals
Slide 3: Bio-Rad Today
Bio-Rad Today Global leader of innovative products in life science research and clinical diagnostics 70+ $2.8B 8,300 Years Strong Annual Sales* Employees Worldwide Performance Continuous Innovation A History of Contribution Key Competencies Fueling Ongoing Growth Complementary Business Segments Leve
Slide 4: Diversified Customer Base & Geographic Profile
Diversified Customer Base & Geographic Profile 70% recurring revenue provides stability and predictability across the business Diversified Customer Base Worldwide Presence Biopharma Hospital Asia-Pacific Labs 17% 23% 32% Clinical Life Diagnostics 21% Science 47% Americas Academic/ 11% Europe, Govt.
Slide 5: Opportunities Across All Product Areas
Opportunities Across All Product Areas 80%+ of sales from products in which Bio-Rad has a leading market position Life Science Clinical Diagnostics Gene Expression Quality Controls Protein Quantitation Immunohematology Bioseparation Infectious Diseases Molecular Biology Diabetes Monitoring Cell Biol
Slide 6: Life Science Strategy & Growth Pillars
Life Science Strategy & Growth Pillars Innovations fueling growth in translational research and biopharma Droplet Digital PCR Biopharma Production Cell Biology Broadening adoption Leveraging our advantages Building on a portfolio with new platforms for new therapeutic modalities of differentiated as
Slide 7: Clinical Diagnostics Strategy & Growth Pillars
Clinical Diagnostics Strategy & Growth Pillars Extending core franchises and enter molecular diagnostics Core Diagnostics Quality Controls & Informatics Molecular Diagnostics Expand installed base Extend utility of lab QC software Leverage RT-PCR and digital PCR globally and cross-sell menu and driv
Slide 8: Droplet Digital PCR Growth Strategy
Droplet Digital PCR Growth Strategy Portfolio innovations driving broader adoption QX ONE QX600 QX Continuum Assay portfolio Automation & Throughput Sensitivity & Multiplexing Price & Workflow extensions Launched 2020 Launched 2022 Launching 2023 Ongoing Biopharma production and Setting a new standa
Slide 9: Biopharma Production Growth Strategy
Biopharma Production Growth Strategy Boosting productivity for purification of complex molecules • R&D investment focus on innovation – higher yields, fewer purification steps • Fuel demand through applications development • Offer breadth of products for varying scale and customer needs • Invest in
Slide 10: Entering Attractive Molecular Diagnostic Markets
GROWTH PILLAR #3 Entering Attractive Molecular Diagnostic Markets A two-pronged approach Digital PCR primed to serve significant clinical opportunities • Digital PCR technology can deliver meaningful value for several clinical applications • $6B clinical opportunity growing at 10%+ • Simple workflow
Slide 11: Advancing Our Continued Transformation — A Three Phased Approach
Advancing Our Continued Transformation — A Three Phased Approach Improving financial performance 3 Accelerated 2 Growth 2023 - 2025 Performance • Mix & market segment focus & Operational • Operating margin expansion Improvement • Channel performance 1 2020 - 2023 • • • Increase innovation Leverage o
Slide 12: Enhancing Our Financial Profile Through 2025
Enhancing Our Financial Profile Through 2025 • Accelerating our revenue growth profile • Further improving our cost structure 8% Target (1)(2) Core Revenue CAGR Currency Neutral • Expanding profitability • Creating shareholder value through prudent 26% capital deployment Target Profitability Adjuste
Slide 13: Environmental & Social Responsibility Goals
Environmental & Social Responsibility Goals Progress on all fronts 2017 Goals for 2030 46% carbon emission reduction 100% renewable electricity 45% women in U.S. leadership roles 60% of U.S. workforce from under-represented groups 25% reduction of non-recyclable packaging 13
Slide 14: Thank you
Thank you Norman Schwartz Chief Executive Officer 14 CONFIDENTIAL / DRAFT
Slide 15: Appendix
Appendix 15 CONFIDENTIAL / DRAFT
Slide 16: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures Year Ended Year Ended December 31, % of December 31, % of 2021 revenue 2022 revenue GAAP net sales $ 2,922,545 $ 2,802,249 Legal settlements (31,843) - Non-GAAP net sales $ 2,890,702 $ 2,802,249 GAAP cost of goods sold $ 1,284,449 $ 1,234,919 Amo
Slide 17: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures Year Ended Year Ended December 31, % of December 31, % of 2021 revenue 2022 revenue GAAP net sales $ 2,922,545 $ 2,802,249 Legal settlements (31,843) - Non-GAAP net sales $ 2,890,702 $ 2,802,249 GAAP selling, general and administrative expense $
Slide 18: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures Year Ended Year Ended December 31, % of December 31, % of 2021 revenue 2022 revenue GAAP net sales $ 2,922,545 $ 2,802,249 Legal settlements (31,843) - Non-GAAP net sales $ 2,890,702 $ 2,802,249 GAAP income from operations $ 500,336 17.1% $ 482,6
Bio-Rad Laboratories — Jefferies Healthcare Conference 2023 on 6ix